



Dnmt3a is an epigenetic mediator of adipose insulin resistance

You, Dongjoo; Nilsson, Emma; Tenen, Danielle E.; Lyubetskaya, Anna; Lo, James C.; Jiang, Rencong; Deng, Jasmine; Dawes, Brian A.; Vaag, Allan; Ling, Charlotte; Rosen, Evan D.; Kang, Sona

Published in:
eLife

DOI:
[10.7554/eLife.30766](https://doi.org/10.7554/eLife.30766)

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license:
[CC BY](#)

Citation for published version (APA):
You, D., Nilsson, E., Tenen, D. E., Lyubetskaya, A., Lo, J. C., Jiang, R., Deng, J., Dawes, B. A., Vaag, A., Ling, C., Rosen, E. D., & Kang, S. (2017). Dnmt3a is an epigenetic mediator of adipose insulin resistance. *eLife*, 6, [e30766]. <https://doi.org/10.7554/eLife.30766>

Dnmt3a is an epigenetic mediator of adipose insulin resistance

Dongjoo You¹, Emma Nilsson², Danielle E Tenen³, Anna Lyubetskaya⁴, James C Lo⁵, Rencong Jiang¹, Jasmine Deng¹, Brian A Dawes³, Allan Vaag^{6,7}, Charlotte Ling², Evan D Rosen^{3,4*}, Sona Kang^{1*}

¹Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States; ²Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Scania University Hospital, Malmö, Sweden; ³Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Boston, United States; ⁴Broad Institute of Harvard and MIT, Cambridge, United States; ⁵Weill Cornell Medical College, New York, United States; ⁶Diabetes and Metabolism, Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; ⁷Early Clinical Development, AstraZeneca, Innovative Medicines, Göteborg, Sweden

Abstract Insulin resistance results from an intricate interaction between genetic make-up and environment, and thus may be orchestrated by epigenetic mechanisms like DNA methylation. Here, we demonstrate that DNA methyltransferase 3a (Dnmt3a) is both necessary and sufficient to mediate insulin resistance in cultured mouse and human adipocytes. Furthermore, adipose-specific Dnmt3a knock-out mice are protected from diet-induced insulin resistance and glucose intolerance without accompanying changes in adiposity. Unbiased gene profiling studies revealed *Fgf21* as a key negatively regulated Dnmt3a target gene in adipocytes with concordant changes in DNA methylation at the *Fgf21* promoter region. Consistent with this, *Fgf21* can rescue Dnmt3a-mediated insulin resistance, and DNA methylation at the *FGF21* locus was elevated in human subjects with diabetes and correlated negatively with expression of *FGF21* in human adipose tissue. Taken together, our data demonstrate that adipose Dnmt3a is a novel epigenetic mediator of insulin resistance in vitro and in vivo.

DOI: <https://doi.org/10.7554/eLife.30766.001>

***For correspondence:**

erosen@bidmc.harvard.edu (EDR);
kangs@berkeley.edu (SK)

Competing interests: The authors declare that no competing interests exist.

Funding: See page 14

Received: 26 July 2017

Accepted: 29 October 2017

Published: 01 November 2017

Reviewing editor: Clifford J Rosen, Maine Medical Center Research Institute, United States

© Copyright You et al. This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Introduction

Insulin resistance (IR) is generally defined as a reduced ability of insulin to provoke metabolic responses, such as glucose uptake. Several mechanistic drivers of IR have been proposed, including defects in the insulin signal transduction pathway, dysfunctional mitochondrial respiration, and ER stress (Boucher et al., 2014; Gregor and Hotamisligil, 2011; Houstis et al., 2006; Ozcan et al., 2004; Samuel and Shulman, 2012). The data supporting the involvement of these non-mutually exclusive pathways are convincing, but additional mechanisms are also likely to participate in the development of IR. Nuclear pathways in particular (i.e. transcriptional and epigenomic mechanisms) are likely to play an important role, given that IR often develops over a time course that is inconsistent with rapid signal transduction events (Kang et al., 2015; Tan et al., 2015). Furthermore, there is a large body of data from humans and rodents indicating that the propensity for IR can be passed transgenerationally; such ‘fetal programming’ studies strongly imply an epigenetic basis for IR (Carone et al., 2010; Heijmans et al., 2008; Li et al., 2010; Tobi et al., 2014). Finally, thiazolidinedione drugs, which activate the transcription factor PPAR γ , provide one of the only pharmacological therapies for IR (Soccio et al., 2014; Step et al., 2014; Sugii et al., 2009). Taken together, these

data strongly suggest that epigenomic and transcriptional mechanisms must be in play in the etiopathogenesis of IR (Kang et al., 2016).

DNA methylation is a reversible epigenetic mark involving the covalent transfer of a methyl group to the C-5 position of a cytosine residue, usually in the context of a CpG doublet, by DNA methyltransferases (Dnmts) (Robertson, 2005). Long thought to be a static epigenetic mark, emerging evidence suggests that methylated DNA undergoes dynamic and reversible remodeling in somatic cells during developmental, physiological, and pathogenic pathophysiological processes (Barres et al., 2013; 2009; Benner et al., 2015; Kirchner et al., 2016; Multhaup et al., 2015; Siersbæk et al., 2017). As an example, a bout of intense exercise can induce DNA hypomethylation at the *PPARGC1a* locus in human skeletal muscle within hours, followed by increased gene expression; these effects were reversed after resting (Barrès et al., 2012). Mounting evidence points to a role for DNA methylation in the pathogenesis of metabolic disorders. For example, the obesity-prone *agouti* mouse has reduced DNA methylation at the regulatory region for the *Agouti* gene, leading to enhanced expression and subsequent inhibition of the satiety-inducing MC4 receptor (Xie et al., 2013). Multiple studies have shown that changes in DNA methylation at key metabolic genes, such as *Cox7a1* (Rönn et al., 2008), *IGF-2* (Heijmans et al., 2008), and *Pomc* (Ehrlich et al., 2010), associate with various metabolic insults including aging, obesity, anorexia, and prenatal exposure to famine. Moreover, recent genome-wide profiling studies have identified distinct global DNA methylation patterns that associate with obesity and diabetes in humans (Dayeh et al., 2014; Feinberg et al., 2010; Kirchner et al., 2016; Multhaup et al., 2015; Nilsson et al., 2015; Volkmar et al., 2012; Volkov et al., 2017). Altered DNA methylation is linked to the transgenerational passage of metabolic disorders (Ng et al., 2010; Wei et al., 2014). Despite numerous studies showing a link between DNA methylation and metabolic dysregulation, the cause-and-effect relationship between the two remains largely unknown.

In mammals, five Dnmt family members have been identified: *Dnmt1*, *Dnmt2* (also known as *Trdm1*), *Dnmt3a*, *Dnmt3b* and *Dnmt3l*, yet only three (*Dnmt1*, *3a*, and *3b*) possess DNA methyltransferase activity (Robertson, 2005). *Dnmt1* (the maintenance DNA methyltransferase) has a preference to methylate hemimethylated DNA whereas *Dnmt3a* and *3b* prefer unmethylated DNA as substrate, and thus act as de novo DNA methyltransferases (Robertson, 2005). *Dnmt3l* is homologous to the other Dnmt3s but lacks catalytic activity (Robertson, 2005) and *Dnmt2* has sequence homology to all Dnmts but methylates cytoplasmic tRNA, and not DNA (Robertson, 2005). Administration of a small molecule Dnmt inhibitor has been shown to improve insulin sensitivity in the setting of obesity, in part by demethylating the *Adipoq* promoter, and a role for *Dnmt1* in this process was suggested by genetic knockdown studies in cultured adipocytes (Kim et al., 2015).

Here, we identify *Dnmt3a* as a key epigenetic determinant of obesity-associated IR in adipose tissue. *Dnmt3a* plays a causal role in the development of cell autonomous IR in mouse and human adipocytes in a manner that is dependent on its catalytic activity. Consistent with results from adipocytes in vitro, we find that adipose-specific *Dnmt3a* deficiency in vivo confers protection from diet-induced IR and glucose tolerance without accompanying changes in body weight or adiposity. In addition, unbiased gene expression profiling suggests that *Dnmt3a* acts as primarily as a gene repressor, and reveals a set of adipocyte-specific target genes, including *Fgf21*. Further, we demonstrate that *Dnmt3a* mediates IR, at least in part, by methylating specific *cis*-regulatory elements in the *Fgf21* gene and thus suppressing its expression. We also provide evidence that similar mechanisms might be at play in human adipose tissue. These studies identify *Dnmt3a* as a novel epigenetic mediator of IR in adipocytes.

Results

Adipose expression of Dnmts inversely correlates with insulin sensitivity

To identify a potential role for Dnmts in the pathogenesis of insulin resistance, we compared their expression levels in insulin-sensitive metabolic tissues (i.e. liver, muscle, and adipose depots) in various metabolic settings. In a diet-induced obesity (DIO) mouse model, *Dnmt1* and *Dnmt3a* mRNA expression was elevated in adipose tissue, especially in epididymal and mesenteric WAT (Figure 1A, Figure 1—figure supplement 1A). *Dnmt3a* expression was significantly induced by HFD in skeletal




Figure 1. Increased adipose expression of Dnmts in obesity. (A) *Dnmt* mRNA expression in adipose from chow- and high fat-fed (HFD) C57Bl/6 mice (A); $n = 6$ mice, $p < 0.05$, Student's *t*-test, mean \pm s.e.m.) and (B) in adipose tissue from *ob/+* and *ob/ob* mice in the presence and absence of rosiglitazone treatment (right; $n = 7$ for *ob/+*, $n = 8$ for *ob/+* plus Rosi, $n = 7$ for *ob/ob* with and without Rosi, $p < 0.05$, Student's *t*-test, mean \pm s.e.m.). (C) Western blot showing Dnmt3a protein levels in adipose tissue from chow vs. HFD mice. (D) Quantification of western blot in (C).

DOI: <https://doi.org/10.7554/eLife.30766.002>

The following source data and figure supplements are available for figure 1:

Source data 1. Figure 1—source data.

DOI: <https://doi.org/10.7554/eLife.30766.005>

Figure supplement 1. Expression of Dnmts in various metabolic tissues.

DOI: <https://doi.org/10.7554/eLife.30766.003>

Figure supplement 1—source data 1. Figure 1—figure supplement 1—source data.

DOI: <https://doi.org/10.7554/eLife.30766.004>

muscle, but to a lesser degree than in adipose tissue. No effect of HFD was observed in liver (**Figure 1—figure supplement 1B–C**). In genetically obese *ob/ob* mice, mRNA expression of all three functional *Dnmts* was elevated in adipose tissue (**Figure 1B**). Importantly, expression of these genes was significantly reduced after treatment with the insulin sensitizer rosiglitazone (Rosi) (**Figure 1B**). Increased adipose expression of Dnmt3a was confirmed by immunoblotting in DIO mice (**Figure 1C, D**). Relative expression of Dnmt3a was higher in eWAT compared to skeletal muscle and liver compared in normal chow-fed mice (**Figure 1—figure supplement 1D–E**). *Dnmt2* and *Dnmt3l* mRNA displayed minimal expression in adipose tissue (not shown). Together, this led us to hypothesize that Dnmts may have a direct functional role in the pathogenesis of adipose IR.

Knock-down of Dnmt3a confers protection from drug-mediated IR

Given the inverse correlation of adipose *Dnmt* expression with insulin sensitivity, we sought to test the cell autonomous role of Dnmts in the development of IR. To that end, individual Dnmts were knocked-down in mature 3T3-L1 adipocytes using two distinct short hairpin RNAs (shRNAs) (**Figure 2—figure supplement 1A–F**). To promote IR, cells were treated with dexamethasone (Dex) and TNF- α (TNF) (Houstis et al., 2006; Kang et al., 2015) for an additional four days. Knock-down of individual Dnmts did not have a major impact on the basal level of insulin sensitivity when assessed by insulin-stimulated glucose uptake (**Figure 2—figure supplement 2A–E**). However, knock-down of *Dnmt3a*, but not *Dnmt1* or *Dnmt3b*, protected adipocytes from Dex- and TNF-mediated IR as assessed by insulin-stimulated glucose uptake and signal transduction (**Figure 2A,B, Figure 2—figure supplement 2A–E**). Given the elevated expression of adipose Dnmts in obesity, we were prompted to test whether overexpression of Dnmts per se is sufficient to drive IR in adipocytes. Individual Dnmts were expressed in mature 3T3-L1 adipocytes by lentiviral delivery. Interestingly, overexpression of *Dnmt3a* and *3b*, but not *Dnmt1*, potentially inhibited insulin-stimulated glucose uptake (**Figure 2C**). Additionally, we tested whether the causal role of *Dnmt3a* in the development of insulin resistance is conserved in human adipocytes. Overexpression of *Dnmt3a* powerfully inhibited insulin-stimulated glucose uptake in in vitro differentiated adipocytes from human adipose derived stem cells (**Figure 2D**). Together, our gain- and loss-of-function studies in vitro show that *Dnmt3a* is both necessary and sufficient to mediate IR in adipocytes in a cell autonomous manner.

DNA methyltransferase activity is critical for Dnmt3a to mediate IR

Studies have shown that *Dnmt3a* can act as a gene repressor using both catalytic-dependent and independent mechanisms (Bachman et al., 2001; Fuks et al., 2001). Thus, we sought to determine whether DNA methyltransferase activity is required to mediate IR. We initially pursued a pharmacological approach, using two synthetic Dnmt inhibitors, 5-azacytidine (5-Aza) (Stresemann and Lyko, 2008), a nucleoside analogue serving as a pseudo-substrate for Dnmts, and RG-108 (Brueckner et al., 2005), a non-nucleoside-based drug. Remarkably, both Dnmt inhibitors blocked Dex- and TNF-mediated IR (**Figure 3A,B, Figure 3—figure supplement 1A,B**). In addition to these synthetic inhibitors, the naturally occurring Dnmt inhibitors (Rajavelu et al., 2011) epigallocatechin gallate (EGCG) and theaflavin-3,3'-digallate (TF-3) also showed insulin-sensitizing activity in the setting of Dex- and TNF-mediated IR (**Figure 3—figure supplement 1C–F**). These data suggest that DNA methyltransferase activity is necessary for *Dnmt3* to cause IR. To further probe this hypothesis, we overexpressed a catalytically inactive allele of *Dnmt3a* (C706S) (Hsieh, 1999). Unlike the wild-type allele, *Dnmt3a* C706S was unable to suppress insulin-stimulated glucose uptake (**Figure 3C**). Together, the pharmacological and genetic evidence indicates that DNA methyltransferase activity is essential for *Dnmt3a* to mediate IR.

Adipose-specific Dnmt3a deficiency confers protection from diet-induced insulin resistance and glucose intolerance

We next sought to determine whether loss of *Dnmt3a* in adipocytes could confer protection from diet-induced adipose tissue and systemic IR in vivo. To address this, we generated adipose-specific *Dnmt3a* knock-out mice (*Dnmt3a*^{AdiKO}) by crossing *Dnmt3a* floxed mice (*Dnmt3a*^{f/f}) (Nguyen et al., 2007) to adiponectin-Cre mice (Eguchi et al., 2011) (**Figure 4—figure supplement 1A,B**). On chow diet, male WT and *Dnmt3a*^{AdiKO} animals did not show any obvious change in their body weight, insulin sensitivity, glucose tolerance, or insulin levels (**Figure 4—figure supplement 2A–D**). On HFD (45% fat), *Dnmt3a*^{AdiKO} mice still showed no significant differences in body weight or composition relative to littermate controls (**Figure 4A,B**). Moreover, the effect of long-term fasting (16 hr) on body weight or body composition did not differ between genotypes (**Figure 4C**), suggesting that gross energy homeostasis is not altered in the knock-out animals. Despite no obvious change in energy balance, high fat fed male *Dnmt3a*^{AdiKO} mice exhibited improved glucose tolerance (**Figure 4D,E**) and insulin sensitivity (**Figure 4F,G**) with reduced serum insulin in the fed state (**Figure 4H**). Consistent with their metabolic improvement, male *Dnmt3a*^{AdiKO} mice display increased insulin signal transduction in adipose tissue, as demonstrated by increased insulin-stimulated phosphorylation of IRS and AKT (**Figure 4I,J**). Similarly, female *Dnmt3a*^{AdiKO} mice display improved insulin sensitivity and glucose tolerance on HFD without a change in body weight (**Figure 4—figure**




Figure 2. Dnmt3a is sufficient and necessary to mediate cell autonomous IR in vitro. (A) Two independent hairpins against Dnmt3a (versus scrambled control shRNA; shScr) were delivered to mature 3T3-L1 adipocytes (Day 8) via lentiviral transduction. Cells were then treated with Dex and TNF for 4 days and assessed for insulin-stimulated glucose uptake (3 H-2-DG assay, $n = 6$, $p < 0.05$). Shown is the % of insulin-stimulated glucose uptake rescued by Dnmt3a knockdown ($n = 6$, $p < 0.05$). (B) Cells in (A) with #2 shDnmt3a hairpin and control cells were withdrawn from serum for 6 hr, stimulated with 20 nM insulin for 5 min and subjected to immunoblotting with antibodies against total and phospho-AKT and -IRS-1 with and without insulin. (C) Basal and insulin-stimulated glucose uptake in mature 3T3-L1 and (D) in in vitro-differentiated primary human adipocytes transduced with lentivirus expressing DnmTs or the empty plasmid vector, pCDH ($n = 6$, $p < 0.05$, Student's t -test, mean \pm s.e.m.).

DOI: <https://doi.org/10.7554/eLife.30766.006>

The following source data and figure supplements are available for figure 2:

Source data 1. Figure 2—source data.

DOI: <https://doi.org/10.7554/eLife.30766.011>

Figure supplement 1. Knock-down efficiency of Dnmt hairpins.

DOI: <https://doi.org/10.7554/eLife.30766.007>

Figure supplement 1—source data 1. Figure 2—figure supplement 1—source data.

DOI: <https://doi.org/10.7554/eLife.30766.008>

Figure supplement 2. Dnmt3a is necessary for Dex- and TNF-mediated IR.

DOI: <https://doi.org/10.7554/eLife.30766.009>

Figure supplement 2—source data 1. Figure 2—figure supplement 2—source data.

DOI: <https://doi.org/10.7554/eLife.30766.010>




Figure 3. DNA methyltransferase activity is critical for Dnmt3a to mediate IR. Insulin-stimulated glucose uptake assay was conducted using 3T3-L1 adipocytes treated with Dnmt inhibitors (**A**, 5-Aza; **B**, RG-108) and Dex or TNF for 4 days. Shown is the % of insulin-stimulated glucose uptake rescued by Dnmt inhibitors ($n = 6$, $p < 0.05$). (**C**) Basal and insulin-stimulated glucose uptake in mature 3T3-L1 adipocytes transduced with wild-type Dnmt3a vs. a catalytically inactive allele (C706S) ($n = 6$, $p < 0.05$, Student's t -test, mean \pm s.e.m.).

DOI: <https://doi.org/10.7554/eLife.30766.012>

The following source data and figure supplements are available for figure 3:

Source data 1. Figure 3—source data.

DOI: <https://doi.org/10.7554/eLife.30766.015>

Figure supplement 1. Dnmt inhibitors confer protection from Dex- and TNF-mediated IR.

DOI: <https://doi.org/10.7554/eLife.30766.013>

Figure supplement 1—source data 1. Figure 3—figure supplement 1—source data.

DOI: <https://doi.org/10.7554/eLife.30766.014>

supplement 3A–C). We next assessed whether insulin sensitization could be due to either enhanced browning or reduced inflammation of WAT. With regard to the former, we found no consistent change in the expression of major thermogenic genes such as *Ucp1* and *Ppargc1a* in either iWAT and BAT (**Figure 4—figure supplement 4A,B**). Additionally, gene expression analysis showed a non-significant trend toward reduced expression of proinflammatory genes such as *Tnfa* and *Ccl2* (which encodes MCP-1) in the eWAT of *Dnmt3a^{AdiKO}* mice (**Figure 4—figure supplement 5A**). We also saw no obvious change in the density of crown-like structures between WT and KO tissues (**Figure 4—figure supplement 5B**). Together, these results demonstrate that adipose-specific deletion of Dnmt3a confers protection from diet-induced IR in a manner that is independent of adiposity, inflammation, or browning of white adipose tissue.

Unbiased gene profiling studies reveal that Fgf21 is a key metabolic target gene of Dnmt3a in adipocytes

Dnmt3a affects developmental processes by regulating non-overlapping sets of cell type-specific target genes (**Challen et al., 2011; Nguyen et al., 2007; Nishikawa et al., 2015**). To gain mechanistic insight into Dnmt3a-mediated IR at the molecular level, we performed RNA-seq in 3T3-L1 adipocytes, in both gain- and loss-of-function contexts. We have successfully used this approach to enhance our ability to identify *bona fide* targets (**Kang et al., 2012**). We found that 97 genes were repressed after shRNA-mediated Dnmt3a knock-down, while only eight genes were up-regulated in the presence of excess Dnmt3a; the single gene showing concordant regulation was Dnmt3a itself (**Figure 5A**). Conversely, 290 genes were induced by Dnmt3a knock-down, and 36 genes showed diminished expression after Dnmt3a overexpression; seven genes were concordantly regulated by both manipulations (**Figure 5B and C** and **Supplementary file 1**). These data are consistent with the expectation that Dnmt3a works primarily as a repressor of gene expression. Among the concordantly-regulated negative target genes of Dnmt3a, we were immediately struck by the presence of *Fgf21*. FGF21 is known to facilitate glucose uptake in adipocytes (**Ge et al., 2011; Lee et al., 2014; Minard et al., 2016**), and is a positive target gene of PPAR γ (**Muise et al., 2008**). Furthermore, mice lacking FGF21 do not support Rosi-mediated insulin sensitization in vivo (**Dutchak et al., 2012**). We confirmed by Q-PCR that *Fgf21* expression is indeed reduced in cultured adipocytes




Figure 4. Adipose-specific *Dnmt3a* KO mice display improved whole body insulin sensitivity and glucose tolerance on HFD. **(A)** Body weight of *Dnmt3a^{AdiKO}* and control mice on HFD ($n = 7, 9$, $p < 0.05$, Student's *t*-test, mean \pm s.e.m.). **(B)** Body composition after 10 weeks of HFD ($n = 7, 9$). **(C)** Effect of long-term fasting (16 hr) on body weight or body composition by EchoMRI. Shown is % loss after fasting ($n = 14, 14$, $p < 0.05$, Student's *t*-test, mean \pm s.e.m.). **(D)** Glucose tolerance test after 9 weeks on HFD ($n = 7, 9$, $p < 0.05$, Student's *t*-test, mean \pm s.e.m.). **(E)** The area under curve (AUC) in **(D)**. **(F)** Insulin tolerance test after 11 weeks on HFD ($n = 7, 9$, $p < 0.05$, Student's *t*-test, mean \pm s.e.m.). **(G)** AUC in **(F)**. **(H)** Fed and fasted insulin levels measured by ELISA ($n = 7, 9$, $p < 0.05$, Student's *t*-test, mean \pm s.e.m.). **(I)** Immunoblot of total and phospho-AKT and IRS-1 in eWAT after IP insulin. **(J)** Quantification of western blot in **(I)**.

DOI: <https://doi.org/10.7554/eLife.30766.016>

The following source data and figure supplements are available for figure 4:

Source data 1. Figure 4—source data.

DOI: <https://doi.org/10.7554/eLife.30766.027>

Figure supplement 1. Adipose-specific deletion of *Dnmt3a*.

DOI: <https://doi.org/10.7554/eLife.30766.017>

Figure supplement 1—source data 1. Figure 4—figure supplement 1—source data.

DOI: <https://doi.org/10.7554/eLife.30766.018>

Figure supplement 2. Metabolic features of *Dnmt3a^{AdiKO}* mice on chow.

DOI: <https://doi.org/10.7554/eLife.30766.019>

Figure supplement 2—source data 1. Figure 4—figure supplement 2—source data.

DOI: <https://doi.org/10.7554/eLife.30766.020>

Figure supplement 3. Metabolic features of female *Dnmt3a^{AdiKO}* on HFD.

DOI: <https://doi.org/10.7554/eLife.30766.021>

Figure supplement 3—source data 1. Figure 4—figure supplement 3—source data.

DOI: <https://doi.org/10.7554/eLife.30766.022>

Figure supplement 4. Gene expression profile of thermogenic genes in *Dnmt3a^{AdiKO}* mice on HFD.

DOI: <https://doi.org/10.7554/eLife.30766.023>

Figure supplement 4—source data 1. Figure 4—figure supplement 4—source data.

DOI: <https://doi.org/10.7554/eLife.30766.024>

Figure 4 continued on next page

Figure 4 continued

Figure supplement 5. Gene expression analysis of proinflammatory genes and histology examination of eWAT from *Dnmt3a^{fl/fl}* and *Dnmt3a^{AdiKO}* mice on HFD.

DOI: <https://doi.org/10.7554/eLife.30766.025>

Figure supplement 5—source data 1. Figure 4—figure supplement 5—source data.

DOI: <https://doi.org/10.7554/eLife.30766.026>

overexpressing *Dnmt3a*, is increased in cells expressing sh*Dnmt3a*, and most importantly, is up-regulated in the adipose tissue of *Dnmt3a^{AdiKO}* mice (**Figure 5D**). Unlike adipose tissue levels, serum levels of *Fgf21* were reduced in HFD-fed *Dnmt3a^{AdiKO}* mice compared to controls (**Figure 5—figure supplement 5**). To determine whether restoration of FGF21 levels could ameliorate *Dnmt3a*-mediated IR, we treated 3T3-L1 adipocytes that overexpress *Dnmt3a* with recombinant FGF21, which restored insulin sensitivity in a dose-dependent manner (**Figure 5E**).

***Dnmt3a*-mediated changes in *Fgf21* gene expression involve changes in DNA methylation**

In general, the level of DNA methylation at gene promoters is inversely correlated with mRNA expression (Jones, 2012). Given the functional significance of FGF21 in *Dnmt3a*-mediated IR, we further examined whether *Dnmt3a* directly alters methylation of the 5 kb upstream promoter regions of the *Fgf21* gene (**Figure 6A**). Using methylated DNA precipitation PCR (MeDIP-qPCR), we detected genomic DNA hypermethylation at *Fgf21* promoter regions in *Dnmt3a* overexpressor 3T3-L1 cells compared to controls (**Figure 6B**). Conversely, DNA hypomethylation of these same regions was seen in *Dnmt3a* knock-down cells (**Figure 6B**). In addition to the in vitro models, we conducted MeDIP-qPCR analysis using genomic DNA from fractionated adipocytes of *Dnmt3a^{AdiKO}* and control animals, finding reduced DNA methylation at the *Fgf21* promoter in KO cells (**Figure 6C**). Consistent with DNA methylation pattern at the *Fgf21* promoter region, co-transfection of *Dnmt3a* potentially inhibited promoter activity of *Fgf21* (**Figure 6D**). Together, these data suggest that *Dnmt3a*-mediated suppression of *Fgf21* involves changes in DNA methylation profile at key promoter regions.

DNA methylation of *FGF21* is increased in human adipose tissue of subjects with type 2 diabetes

To translate some of our findings to humans, we investigated DNA methylation and gene expression of *FGF21* in human adipose tissue collected from diabetic vs. non-diabetic human subjects. In line with our mouse data, we found hypermethylation of four CpG sites annotated to *FGF21* in adipose tissue of subjects with type 2 diabetes compared with non-diabetic controls (**Figure 7A** and **Supplementary file 2**). Further, we found a negative correlation between DNA methylation and mRNA expression of *FGF21* in human adipose tissue (**Figure 7B–E**). Together, these data support a role for increased DNA methylation of *FGF21* in the regulation of adipose *FGF21* expression in association with metabolic disease.

Discussion

While genetics plays an important role in obesity and T2D, genetic differences cannot fully explain many features of these conditions, such as discordance in monozygotic twins, and the close relationship with lifestyle factors (McCarthy, 2010; Morris et al., 2012; Voight et al., 2010; Zeggini et al., 2008). Of note, the vast majority of GWAS-proven allelic variants associated with T2D correspond much better to altered insulin secretion and islet function rather than to IR per se (Voight et al., 2010). Hence, forms of non-genetic variation, such as epigenetic alterations, must also be considered. This notion has been borne out by a recent epigenome-wide association study (EWAS) linking alterations in DNA methylation to whole-body insulin sensitivity (Zhao et al., 2012). Importantly, even genetic variants may cause disease in a DNA methylation-dependent manner, as has recently been shown for T2D and obesity (Dayeh et al., 2013; Elliott et al., 2017; Nilsson et al., 2014; Olsson et al., 2014; Volkov et al., 2016). We have also shown that adipose tissue from patients with T2D exhibit numerous methylation and expression differences relative to unrelated healthy controls, with many of the same changes also seen in twin pairs discordant for T2D (Nilsson et al.,




Figure 5. *Fgf21* is a key target gene of *Dnmt3a*. Venn diagram showing the number of positive (A) and negative (B) *Dnmt3a* target genes through comparative analysis of RNA-seq profiles from *Dnmt3a* knockdown and overexpressing adipocytes. (C) Heat map showing differentially regulated genes by *Dnmt3a* overexpression and knock-down. Group 1: Genes that are down-regulated by *Dnmt3a* overexpression; Group 2: Genes that are down-regulated by *Dnmt3a* overexpression and up-regulated by *Dnmt3a* knock-down; Group 3: Genes that are up-regulated by *Dnmt3a* knock-down. (D) *Fgf21* mRNA expression in *Dnmt3a* overexpressor (left) and knock-down (middle) L1 adipocytes and in fractionated adipocytes (right) from *Dnmt3a*^{AdiKO} and *Dnmt3a*^{f/f} mice on HFD (n = 5). (E) Mature 3T3-L1 adipocytes expressing GFP or *Dnmt3a* treated with indicated amount of recombinant *Fgf21* for 48 hr (or vehicle), and tested for insulin sensitivity by ³H-2-DG assay. Shown is basal and insulin-stimulated glucose uptake. (n = 6 mice, p<0.05, Student's *t*-test, mean ±s.e.m.).

DOI: <https://doi.org/10.7554/eLife.30766.028>

The following source data and figure supplements are available for figure 5:

Source data 1. Figure 5—source data.

DOI: <https://doi.org/10.7554/eLife.30766.031>

Figure supplement 1. Serum *Fgf21* levels in *Dnmt3a*^{AdiKO} mice.

DOI: <https://doi.org/10.7554/eLife.30766.029>

Figure supplement 1—source data 1. Figure 5—figure supplement 1—source data.

DOI: <https://doi.org/10.7554/eLife.30766.030>

2014). In this study, we identified increased expression of an enzymatic effector of DNA methylation, *Dnmt3a*, as a key epigenetic driver of IR in vitro and in vivo.

DNA methylation, like other forms of epigenomic modification, has been an attractive therapeutic target because of their plasticity and because they offer an opportunity to reprogram cells into a more healthy state. For example, administration of pan-inhibitors of histone deacetylase exerts beneficial metabolic effects in both mice and humans, such as increased energy expenditure, insulin sensitivity and secretion (Christensen et al., 2011; Daneshpajoo et al., 2017; Sharma and Taliyan, 2016; Ye, 2013). DNA methyltransferase inhibitors have also been shown to have an insulin-




Figure 6. Dnmt3a-mediated methylation of the *Fgf21* gene promoter. (A) Schematic showing the tested regions for MeDIP-qPCR at the *Fgf21* locus. Target regions were chosen using MethFinder (<http://www.urogene.org/methprimer>) on regions proximal (5 kb) and distal (50 kb) to the *Fgf21* transcription start site. (B) MeDIP-qPCR was performed using genomic DNA extracted from 3T3-L1 adipocytes transduced with GFP vs. Dnmt3a or shScr vs. shDnmt3a. Shown is relative fold enrichment of 5mC of Dnmt3a overexpressor and KD cells over control cells. (C) MeDIP-qPCR was performed using genomic DNA from Dnmt3a KO and Flox mice on HFD. Shown is relative fold enrichment of 5mC of KO over WT samples. (D) *Fgf21*-promoter reporter (1497/+5) assay performed by co-transfection of the indicated amounts of Dnmt3a expression vector. ($n = 3$ mice, $p < 0.05$, Student's t-test, mean \pm s.e.m.).

DOI: <https://doi.org/10.7554/eLife.30766.032>

The following source data is available for figure 6:

Source data 1. Figure 6—source data.

DOI: <https://doi.org/10.7554/eLife.30766.033>

sensitizing effect in vivo and in vitro (Kim et al., 2015). In line with pharmacological studies, mutant mouse models carrying loss-of function histone modifiers (e.g. *Mll2*, *Ehmt1*, *Jmhd2a* *Lsd1*) were shown to have profound impact on whole body metabolism (Lee et al., 2006; Ohno et al., 2013; Sambeat et al., 2016; Tateishi et al., 2009; Zeng et al., 2016). It should be noted that metabolic consequences in mouse models carrying mutations of histone modifiers appear to be mainly attributable to changes in body weight. Unlike these examples, adipose-specific Dnmt3a KO mice are relatively unique in that they display improved insulin sensitivity without a change in adiposity or body weight. Similarly, the effect on insulin action is not dependent on increased beige or brown adipocytes, or on reducing intra-adipose inflammation.

Our in vitro study indicates that overexpression of Dnmt3a is sufficient to induce cell autonomous IR, however, it does not seem to be the case in vivo. Kamei et al showed that transgenic expression of Dnmt3a per se was not sufficient to render whole body IR and glucose intolerance (Kamei et al., 2010) on chow, HFD, or high methyl diet with chow diet. Authors observed only a mild increase in the gene expression of proinflammatory cytokines (i.e. *Mcp1* and *Tnfa*) when animals were put on HFD. It should be noted that the major caveat of this study is the use of aP2 promoter to drive the transgene expression (Jeffery et al., 2014; Kang et al., 2014; Lee et al., 2013); Potentially, non-adipose expression and earlier expression during development might have a compounding factor in this study. Despite these notions, it will be highly interesting to address how the combination of




Figure 7. *FGF21* DNA methylation in adipose tissue from subjects with T2D compared with controls. (A) Four CpG sites annotated to *FGF21* with significant difference in adipose tissue DNA methylation between subjects with type 2 diabetes and controls. ($p < 0.01$, paired Wilcoxon statistics, mean \pm s.d.). (B–D) Correlations between DNA methylation and mRNA expression for CpG sites significantly associated with T2D in human adipose tissue. (r = Pearson correlation coefficient.).

DOI: <https://doi.org/10.7554/eLife.30766.034>

high methyl donor diet and HFD would affect the metabolic profile of these transgenic animals compared to controls.

Our unbiased gene expression profiling studies led us to identify *Fgf21* as a key target gene in adipocytes, and the data from diabetic humans suggests that this could be a conserved mechanism of IR in both mice and humans. *Fgf21* is better known as a hepatokine, and the liver is the main source of circulating *Fgf21* (Markan et al., 2014). Adipose *Fgf21* probably does not circulate, but rather acts in an autocrine/paracrine manner (Dutchak et al., 2012; Markan et al., 2014). In fact, levels of *Fgf21* in serum were moderately reduced in *Dnmt3a* KO animals compared to controls, in contrast to significantly elevated adipose tissue levels. Studies have shown a positive correlation between insulin and circulating *Fgf21* levels (Chavez et al., 2009; Chen et al., 2008; Zhang et al., 2008), suggesting that insulin may be a key determinant of *Fgf21* in serum. Thus, it is possible that the reduced insulin levels in *Dnmt3a* KO mice on HFD may have led to reduction of *Fgf21* production in liver. This notion is in line with the finding that *Fgf21* serum levels are often elevated in obesity-associated IR (Fisher and Maratos-Flier, 2016; Morrice et al., 2017), possibly reflecting resistance to *Fgf21* (Fisher et al., 2010).

We propose that the local activity of *Fgf21* within the fat pad is important for the improved insulin sensitivity in the knock-out mice, although formal proof of this idea would require generating adipose tissue-specific *Dnmt3a* and *Fgf21* double knockout mice. In line with this view, there are previous studies indicating that adipose *Fgf21* is insulin-sensitizing. For example, three independent studies demonstrated that mutant mice devoid of *Fgf21* signaling in adipose tissue secondary to ablation of *FGFR1* or *bKlotho*, were refractory to the insulin-sensitizing effect of *Fgf21* administration

(Adams et al., 2013; BonDurant et al., 2017; Ding et al., 2012). Some of these studies (Adams et al., 2013; Ding et al., 2012) suggested that adiponectin is an essential mediator of Fgf21 metabolic action; the other study (BonDurant et al., 2017) suggested that adiponectin is dispensable. In our studies, albeit it did not reach statistical significance, there was a trend toward increased mRNA expression of *Adipoq* in both L1 and primary Dnmt3a KO adipocytes (not shown).

Control of Fgf21 expression appears to be highly tissue-specific. For example, PPAR γ is an important driver of Fgf21 in adipose tissue, while PPAR α serves that role in liver (Dutchak et al., 2012). Other studies have also demonstrated that Fgf21 is positively regulated by PPAR γ in fat (Muise et al., 2008; Wang et al., 2008). In addition to focused studies on *Fgf21* promoter regions, global DNA methylation profiling will be necessary to identify differentially methylated regions in the setting of Dnmt3a gain- and loss-of function.

A recent study demonstrated that Dnmt1 may contribute to obesity-associated inflammation and insulin resistance by promoting hypermethylation at the *Adipoq* locus (Kim et al., 2015). Concordant with this study, we also see elevated Dnmt1 levels in the adipose tissue of obese animals. However, knockdown of Dnmt1 did not rescue insulin sensitivity in the setting of Dex or TNF, and overexpression of Dnmt1 did not reduce insulin-stimulated glucose uptake in cultured adipocytes. Based on those criteria, we chose to focus on Dnmt3a, and showed that adipose-specific deletion of this gene promoted insulin sensitivity even in weight-matched obese animals. Of note, we did not identify *Adipoq* as a regulated target after either deletion or overexpression of Dnmt3a.

Despite some effort, we have not yet identified the mechanism by which Dnmt3a expression is increased in obesity. We found that Dnmt3a is not induced by lipids (e.g. palmitate), pro-inflammatory signals (e.g. IL-6, LPS), high doses of insulin, or high glucose in cultured adipocytes (not shown). In our study, in vivo administration of thiazolidinediones normalized the expression of Dnmt3a in *ob/ob* mice but not in lean control animals. The mechanism by which PPAR γ represses gene expression is not entirely clear. Trans-repression through binding of inflammatory transcription factors like NF- κ B and AP-1 has been proposed as a general mechanism for this type of effect (Glass and Saijo, 2010) although we note that there are PPAR γ binding sites near the *Dnmt3a* TSS (not shown). It is thus unclear if direct or indirect (i.e. trans-repression) mechanisms account for the actions of rosiglitazone on *Dnmt3a* expression in obesity.

In summary, we have identified a novel role for Dnmt3a as an epigenetic mediator of adipose IR in vitro and in vivo. Future studies will be required to fully elucidate the full range of its target genomic regions and metabolic effects.

Materials and methods

Cell culture

3T3-L1 preadipocytes were obtained from ATCC and maintained and differentiated as described (Kang et al., 2012). These cells were authenticated by the ability to differentiate and confirmed to be mycoplasma negative. To generate lentivirus particles, lentiviral constructs were co-transfected with pM2DG- and psPAX-expressing plasmids into 293T cells. After 48 hr, virus-containing supernatant was collected, filtered through 0.45 μ m filters, and added to mature 3T3-L1 adipocytes for 24 hr along with 8 μ g/ml Polybrene. Transduction efficiency was determined by comparison with cells transduced in parallel with a GFP-expressing lentivirus. For the ex vivo system, subcutaneous adipose tissue from wild-type C57Bl/6 mice was fractionated with digestion buffer (10 mg/ml collagenase D, 2.4 units of dispase II, 10 mM CaCl₂ in PBS). Cells from the stromal-vascular fraction (SVF) were plated in culture and differentiated as described previously (Qureshi et al., 2014). To differentiate hASCs, Rosi (5 μ M) was added in addition to IBMX (0.5 mM), insulin (5 μ g/ml), and dexamethasone (1 μ M), from day 0–2.

³H-2-DG assay

Mature 3T3-L1 adipocytes were incubated in serum-free DMEM for 4–6 hr. Cells were then washed three times with KRH buffer (12 mM HEPES, pH 7.4, 121 mM NaCl, 5 mM KCl, 0.33 mM CaCl₂, and 1.2 mM MgSO₄) and incubated for 20 min in KRH buffer in the absence or presence of 50 nM insulin. Cells were treated with 2-deoxy-d-[2,6-³H]-glucose (0.33 μ Ci/ml) for another 10 min. Glucose uptake was stopped quickly by three rapid washes with KRH buffer containing 200 mM glucose and 10 μ M

cytochalasin B on ice. Cells were solubilized in 0.1% SDS for 30 min, and radioactivity was measured by liquid scintillation counting.

Reagents

2-Deoxy-d-[2,6-³H]-glucose was purchased from PerkinElmer NEN radiochemicals. Insulin, dexamethasone, isobutylmethylxanthine (IBMX), cytochalasin B, glucose, 2-deoxyglucose, 5-Aza, ECCG, and TF-3 were purchased from Sigma-Aldrich. Recombinant TNF- α and Fgf21 were purchased from Millipore. RG-108 was purchased from Stemgent.

Antibodies

Antibodies were purchased from Cell Signaling (Dnmt3a, 3598S; Akt, 9272; pAkt [S473], 3787; IRS-1, 2382), and from Thermo Fisher (β -actin, MA5-14739, pIRS1[pY612], 44–816G).

Animals

For rosiglitazone studies, female mice *ob/ob* and *ob/+* were treated starting at 8 weeks of age with rosiglitazone by gavage (10 mg/kg body weight) in 0.5% carboxymethylcellulose versus 0.5% carboxymethylcellulose vehicle control daily for 6 weeks. For chow and high-fat feeding studies, male C57Bl/6J mice were put on diet beginning at 8 weeks of age and continued for three months ($n = 8$ per dietary condition). Samples were collected from the perigonadal fat pad.

For histology, adipose tissues were fixed with neutral-buffered formalin and embedded in paraffin and sections were stained with H&E.

For in vivo insulin signaling assay, after overnight fast, insulin (10 U/kg, 5 min) or saline IP were given to WT and KO mice on HFD. After 10 min various tissues were harvested and stored at -80°C until use. Tissue samples were homogenized in cell signaling lysis buffer containing protease inhibitors (Roche) and phosphatase inhibitors (Sigma-Aldrich) and subjected to western blotting. All animal work was approved by the BIDMC IACUC and/or the UC Berkeley ACUC.

RNA extraction and quantitative PCR

Total RNA was extracted from cells or tissues using TRIzol reagent according to the manufacturer's instructions. cDNA was reverse-transcribed from 1 μg of RNA using the RETROscript first strand synthesis kit (Ambion). Quantitative PCR (qPCR) was performed with SYBR Green qPCR Master Mix (Applied Biosystems) using a 7900HT Fast Real-Time PCR System (Applied Biosystems) and CFX96 Touch (Bio Rad). Primer sequences are listed in **Supplementary file 3**. The relative amount of mRNA normalized to cyclophilin B was calculated using the delta-delta method (Livak and Schmittgen, 2001).

Plasmids

Hairpins against Dnmt1, Dnmt3a, and Dnmt3b were purchased from Sigma. Lentiviral overexpression vectors for Dnmt1, 3a, and 3b were subcloned into pCDH using various multicloning sites (XbaI/NotI for Dnmt1, EcoRI/NotI for Dnmt1, Dnmt3a, Dnmt3a-CM) and NotI sites and hairpins targeting *Dnmts* were subcloned at AgeI/EcoRI or purchased from Open Biosystems. Hairpin sequences are shown in **Supplementary file 3**. Fgf21-luc (1497/+5) was generously provided by Dr. Steven Kliewer (UT Southwestern).

MeDIP-qPCR

Genomic DNA was sheared by sonication to an average of 200–800 bp size. Two microgram of denatured DNA was incubated with 2 μg of anti-5-methylcytidine antibody (Epigentek) in IP buffer (10 mM Na-Phosphate pH 7.0, 0.14 M NaCl, 0.05% Triton X-100) for 2 hr at 4°C . Antibody-bound DNA was collected with 20 μl of Dynabeads anti-mouse IgG (Invitrogen Dynal, Oslo, Norway) for 1 hr at 4°C on a rotating wheel and successively washed five times with washing buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), and twice with TE (10 mM Tris-Cl, 1 mM EDTA pH 8.0). DNA was recovered in digestion buffer 125 μl buffer (50 mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS, 35 μg proteinase K) and incubated for 3 hr at 65°C . Recovered DNA was used for qPCR analysis. Primers for MeDIP-qPCR studies are listed in **Supplementary file 3**. All data are normalized to input.

RNA-seq studies

mRNA was purified from 100 ng of total RNA using the Ribo-Zero Magnetic Gold Kit (catalog MRZG126, Illumina). Libraries were prepared using the TruSeq RNA Library Preparation Kit v2 (catalog RS-122–2001, Illumina) according to the manufacturer's protocol starting with the EPF step. Sequencing was performed on the Illumina HiSeq2500. RNA-Seq data are aligned using TopHat2 (Kim *et al.*, 2013). Reads are assigned to transcripts using featureCounts and an mm9 genome modified to minimize overlapping transcripts (Liao *et al.*, 2014). Differential expression analysis of the data is performed using EdgeR (Robinson *et al.*, 2010).

DNA methylation and mRNA expression in human adipose tissue

DNA methylation was analyzed in adipose tissue from 28 subjects with type 2 diabetes and 28 controls as well as in adipose tissue of 14 monozygotic twin pairs ($n = 28$) using Infinium HumanMethylation450 BeadChips (Illumina) according to our previous study where we also present the characteristics of these subjects (Nilsson *et al.*, 2014). Their characteristics are presented in **Supplementary file 4**. mRNA was analyzed in adipose tissue from the 12 monozygotic twin pairs ($n = 24$) using GeneChip Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA) according to the manufacturer's recommendations. In the present study, we studied mRNA expression and DNA methylation of CpG sites annotated to FGF21. DNA and RNA were extracted from human adipose tissue as presented (Nilsson *et al.*, 2014).

Acknowledgements

Work was funded by NIH R01 102173, 102170, and 085171 to EDR and AHA Award #15SDG25240017 to SK. We thank Jeff Leung for technical assistance and the Rosen and the Kang Lab members for helpful conversations. We are also grateful to Drs. Hei Sook Sul, Jen-Chywan Wally Wang, and Andreas Stahl for constructive comments.

Additional information

Funding

Funder	Grant reference number	Author
National Institutes of Health	102173	Evan D Rosen
National Institutes of Health	102170	Evan D Rosen
National Institutes of Health	085171	Evan D Rosen
American Heart Association	15SDG25240017	Sona Kang
National Institutes of Health	116008	Sona Kang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

Dongjoo You, Formal analysis, Validation, Investigation, Carried out most of biological experiments and assisted with preparing the manuscript; Emma Nilsson, Data curation, Formal analysis, Investigation, Collected human adipose tissue and analyzed DNA methylation and gene expression with human sample; Danielle E Tenen, Investigation, Methodology, Generated RNA-Seq library; Anna Lyubetskaya, Formal analysis, Generated and analyzed RNA-Seq data; James C Lo, Resources, Helped with metabolic characterization of knock-out mouse models; Rencong Jiang, Investigation, Carried out insulin signaling assay; Jasmine Deng, Investigation, Carried out gene expression analysis of several biological experiments; Brian A Dawes, Formal analysis, Helped with RNA-Seq data analysis, Generated figures, Submitted GEO data; Allan Vaag, Investigation, Collected human adipose tissue and analyzed DNA methylation and gene expression with human sample; Charlotte Ling, Resources, Investigation, Collected human adipose tissue and analyzed DNA methylation and gene expression data, Supervised overall human data set; Evan D Rosen, Supervision, Funding acquisition,

Writing—original draft, Writing—review and editing, Supervised experiments and edited the manuscript and revision for the revision; Sona Kang, Supervision, Investigation, Writing—original draft, Writing—review and editing, Designed most of biological experiments, Supervised experiments, Wrote draft and revision for the revision

Author ORCIDs

Sona Kang  <https://orcid.org/0000-0002-9831-677X>

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal work was approved by the BIDMC IACUC (056-2017) and/or the UC Berkeley ACUC (AUP-2015-08-7887).

Decision letter and Author response

Decision letter <https://doi.org/10.7554/eLife.30766.041>

Author response <https://doi.org/10.7554/eLife.30766.042>

Additional files

Supplementary files

- Supplementary file 1. Genes that are up-regulated (UP) and down-regulated (DOWN) Dnmt3a vs. GFP and shDnmt3a/shScr.

DOI: <https://doi.org/10.7554/eLife.30766.035>

- Supplementary file 2. DNA methylation of four CpG sites annotated to Fgf21 showing differential DNA methylation in adipose tissue of a case control study for type 2 diabetes.

DOI: <https://doi.org/10.7554/eLife.30766.036>

- Supplementary file 3. Oligonucleotide sequences used in this manuscript.

DOI: <https://doi.org/10.7554/eLife.30766.037>

- Supplementary file 4. Clinical characteristics of study subjects included in the discordant twin cohort and the case control cohort.

DOI: <https://doi.org/10.7554/eLife.30766.038>

- Transparent reporting form

DOI: <https://doi.org/10.7554/eLife.30766.039>

References

- Adams AC, Coskun T, Cheng CC, O Farrell LS, Dubois SL, Kharitonov A. 2013. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazolidinediones. *Molecular Metabolism* **2**:205–214. DOI: <https://doi.org/10.1016/j.molmet.2013.05.005>, PMID: 24049735
- Bachman KE, Rountree MR, Baylin SB. 2001. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. *Journal of Biological Chemistry* **276**:32282–32287. DOI: <https://doi.org/10.1074/jbc.M104661200>, PMID: 11427539
- Barres R, Kirchner H, Rasmussen M, Yan J, Kantor FR, Krook A, Näslund E, Zierath JR. 2013. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. *Cell Reports* **3**:1020–1027. DOI: <https://doi.org/10.1016/j.celrep.2013.03.018>, PMID: 23583180
- Barrès R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, Krook A, Zierath JR. 2009. Non-CpG methylation of the PGC-1α promoter through DNMT3B controls mitochondrial density. *Cell Metabolism* **10**:189–198. DOI: <https://doi.org/10.1016/j.cmet.2009.07.011>, PMID: 19723495
- Barrès R, Yan J, Egan B, Trebak JT, Rasmussen M, Fritz T, Caidahl K, Krook A, O’Gorman DJ, Zierath JR. 2012. Acute exercise remodels promoter methylation in human skeletal muscle. *Cell Metabolism* **15**:405–411. DOI: <https://doi.org/10.1016/j.cmet.2012.01.001>, PMID: 22405075
- Benner C, Isoda T, Murre C. 2015. New roles for DNA cytosine modification, eRNA, anchors, and superanchors in developing B cell progenitors. *PNAS* **112**:12776–12781. DOI: <https://doi.org/10.1073/pnas.1512995112>, PMID: 26417104

- BonDurant LD**, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR, Walsh SA, Ornitz DM, Potthoff MJ. 2017. FGF21 regulates metabolism through adipose-dependent and -independent mechanisms. *Cell Metabolism* **25**:935–944. DOI: <https://doi.org/10.1016/j.cmet.2017.03.005>, PMID: 28380381
- Boucher J**, Kleinridders A, Kahn CR. 2014. Insulin receptor signaling in normal and insulin-resistant states. *Cold Spring Harbor Perspectives in Biology* **6**:a009191. DOI: <https://doi.org/10.1101/cshperspect.a009191>, PMID: 24384568
- Brueckner B**, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M, Lyko F. 2005. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. *Cancer Research* **65**:6305–6311. DOI: <https://doi.org/10.1158/0008-5472.CAN-04-2957>, PMID: 16024632
- Carone BR**, Fauquier L, Habib N, Shea JM, Hart CE, Li R, Bock C, Li C, Gu H, Zamore PD, Meissner A, Weng Z, Hofmann HA, Friedman N, Rando OJ. 2010. Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. *Cell* **143**:1084–1096. DOI: <https://doi.org/10.1016/j.cell.2010.12.008>, PMID: 21183072
- Challen GA**, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, Godley LA, Li W, Goodell MA. 2011. Dnmt3a is essential for hematopoietic stem cell differentiation. *Nature Genetics* **44**:23–31. DOI: <https://doi.org/10.1038/ng.1009>, PMID: 22138693
- Chavez AO**, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. 2009. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. *Diabetes Care* **32**:1542–1546. DOI: <https://doi.org/10.2337/dc09-0684>, PMID: 19487637
- Chen WW**, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G. 2008. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. *Experimental and Clinical Endocrinology & Diabetes* **116**:65–68. DOI: <https://doi.org/10.1055/s-2007-985148>, PMID: 17926232
- Christensen DP**, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N, Grunnet LG, Mandrup-Poulsen T. 2011. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. *Molecular Medicine* **17**:378–390. DOI: <https://doi.org/10.2119/molmed.2011.00021>, PMID: 21274504
- Daneshpajoo M**, Bacos K, Bysani M, Bagge A, Ottosson Laakso E, Vikman P, Eliasson L, Mulder H, Ling C. 2017. HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells. *Diabetologia* **60**:116–125. DOI: <https://doi.org/10.1007/s00125-016-4113-2>, PMID: 27796421
- Dayeh TA**, Olsson AH, Volkov P, Almgren P, Rönn T, Ling C. 2013. Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets. *Diabetologia* **56**:1036–1046. DOI: <https://doi.org/10.1007/s00125-012-2815-7>, PMID: 23462794
- Dayeh T**, Volkov P, Salö S, Hall E, Nilsson E, Olsson AH, Kirkpatrick CL, Wollheim CB, Eliasson L, Rönn T, Bacos K, Ling C. 2014. Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. *PLoS Genetics* **10**:e1004160. DOI: <https://doi.org/10.1371/journal.pgen.1004160>, PMID: 24603685
- Ding X**, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, Kliewer SA. 2012. β Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. *Cell Metabolism* **16**:387–393. DOI: <https://doi.org/10.1016/j.cmet.2012.08.002>, PMID: 22958921
- Dutchak PA**, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA. 2012. Fibroblast growth factor-21 regulates PPAR γ activity and the antidiabetic actions of thiazolidinediones. *Cell* **148**:556–567. DOI: <https://doi.org/10.1016/j.cell.2011.11.062>, PMID: 22304921
- Eguchi J**, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J, Estall JL, Klein U, Maratos-Flier E, Rosen ED. 2011. Transcriptional control of adipose lipid handling by IRF4. *Cell Metabolism* **13**:249–259. DOI: <https://doi.org/10.1016/j.cmet.2011.02.005>, PMID: 21356515
- Ehrlich S**, Weiss D, Burghardt R, Infante-Duarte C, Brockhaus S, Muschler MA, Bleich S, Lehmkuhl U, Frieling H. 2010. Promoter specific DNA methylation and gene expression of POMC in acutely underweight and recovered patients with anorexia nervosa. *Journal of Psychiatric Research* **44**:827–833. DOI: <https://doi.org/10.1016/j.jpsychires.2010.01.011>, PMID: 20176366
- Elliott HR**, Shihab HA, Lockett GA, Holloway JW, McRae AF, Smith GD, Ring SM, Gaunt TR, Relton CL. 2017. Role of DNA methylation in Type 2 diabetes etiology: using Genotype as a causal anchor. *Diabetes* **66**:1713–1722. DOI: <https://doi.org/10.2337/db16-0874>, PMID: 28246294
- Feinberg AP**, Irizarry RA, Fradin D, Aryee MJ, Murakami P, Aspelund T, Eiriksdottir G, Harris TB, Launer L, Gudnason V, Fallin MD. 2010. Personalized epigenomic signatures that are stable over time and covary with body mass index. *Science Translational Medicine* **2**:49ra67. DOI: <https://doi.org/10.1126/scitranslmed.3001262>, PMID: 20844285
- Fisher FM**, Chui PC, Antonellis PJ, Bina HA, Kharitonov A, Flier JS, Maratos-Flier E. 2010. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. *Diabetes* **59**:2781–2789. DOI: <https://doi.org/10.2337/db10-0193>, PMID: 20682689
- Fisher FM**, Maratos-Flier E. 2016. Understanding the physiology of FGF21. *Annual Review of Physiology* **78**:223–241. DOI: <https://doi.org/10.1146/annurev-physiol-021115-105339>, PMID: 26654352
- Fuks F**, Burgers WA, Godin N, Kasai M, Kouzarides T. 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. *The EMBO Journal* **20**:2536–2544. DOI: <https://doi.org/10.1093/emboj/20.10.2536>, PMID: 11350943

- Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. 2011. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. *Journal of Biological Chemistry* **286**:34533–34541. DOI: <https://doi.org/10.1074/jbc.M111.248591>, PMID: 21846717
- Glass CK, Saijo K. 2010. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. *Nature Reviews Immunology* **10**:365–376. DOI: <https://doi.org/10.1038/nri2748>, PMID: 20414208
- Gregor MF, Hotamisligil GS. 2011. Inflammatory mechanisms in obesity. *Annual Review of Immunology* **29**:415–445. DOI: <https://doi.org/10.1146/annurev-immunol-031210-101322>, PMID: 21219177
- Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE, Lumey LH. 2008. Persistent epigenetic differences associated with prenatal exposure to famine in humans. *PNAS* **105**:17046–17049. DOI: <https://doi.org/10.1073/pnas.0806560105>, PMID: 18955703
- Houstis N, Rosen ED, Lander ES. 2006. Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature* **440**:944–948. DOI: <https://doi.org/10.1038/nature04634>, PMID: 16612386
- Hsieh CL. 1999. In vivo activity of murine de novo methyltransferases, Dnmt3a and Dnmt3b. *Molecular and Cellular Biology* **19**:8211–8218. DOI: <https://doi.org/10.1128/MCB.19.12.8211>, PMID: 10567546
- Jeffery E, Berry R, Church CD, Yu S, Shook BA, Horsley V, Rosen ED, Rodeheffer MS. 2014. Characterization of Cre recombinase models for the study of adipose tissue. *Adipocyte* **3**:206–211. DOI: <https://doi.org/10.4161/adip.29674>, PMID: 25068087
- Jones PA. 2012. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nature Reviews Genetics* **13**:484–492. DOI: <https://doi.org/10.1038/nrg3230>, PMID: 22641018
- Kamei Y, Suganami T, Ehara T, Kanai S, Hayashi K, Yamamoto Y, Miura S, Ezaki O, Okano M, Ogawa Y. 2010. Increased expression of DNA methyltransferase 3a in obese adipose tissue: studies with transgenic mice. *Obesity* **18**:314–321. DOI: <https://doi.org/10.1038/oby.2009.246>, PMID: 19680236
- Kang S, Akerblad P, Kiviranta R, Gupta RK, Kajimura S, Griffin MJ, Min J, Baron R, Rosen ED. 2012. Regulation of early adipose commitment by Zfp521. *PLoS Biology* **10**:e1001433. DOI: <https://doi.org/10.1371/journal.pbio.1001433>, PMID: 23209378
- Kang S, Kong X, Rosen ED. 2014. Adipocyte-specific transgenic and knockout models. *Methods in Enzymology* **537**:1–16. DOI: <https://doi.org/10.1016/B978-0-12-411619-1.00001-X>, PMID: 24480338
- Kang S, Tsai LT, Zhou Y, Everts A, Xu S, Griffin MJ, Issner R, Whitton HJ, Garcia BA, Epstein CB, Mikkelsen TS, Rosen ED. 2015. Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis. *Nature Cell Biology* **17**:44–56. DOI: <https://doi.org/10.1038/ncb3080>, PMID: 25503565
- Kang S, Tsai LT, Rosen ED. 2016. Nuclear mechanisms of insulin resistance. *Trends in Cell Biology* **26**:341–351. DOI: <https://doi.org/10.1016/j.tcb.2016.01.002>, PMID: 26822036
- Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. 2013. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biology* **14**:R36. DOI: <https://doi.org/10.1186/gb-2013-14-4-r36>, PMID: 23618408
- Kim AY, Park YJ, Pan X, Shin KC, Kwak SH, Bassas AF, Sallam RM, Park KS, Alfadda AA, Xu A, Kim JB. 2015. Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance. *Nature Communications* **6**:7585. DOI: <https://doi.org/10.1038/ncomms8585>, PMID: 26139044
- Kirchner H, Sinha I, Gao H, Ruby MA, Schönte M, Lindvall JM, Barrès R, Krook A, Näslund E, Dahlman-Wright K, Zierath JR. 2016. Altered DNA methylation of glycolytic and lipogenic genes in liver from obese and type 2 diabetic patients. *Molecular Metabolism* **5**:171–183. DOI: <https://doi.org/10.1016/j.molmet.2015.12.004>, PMID: 26977391
- Lee S, Lee DK, Dou Y, Lee J, Lee B, Kwak E, Kong YY, Lee SK, Roeder RG, Lee JW. 2006. Coactivator as a target gene specificity determinant for histone H3 lysine 4 methyltransferases. *PNAS* **103**:15392–15397. DOI: <https://doi.org/10.1073/pnas.0607313103>, PMID: 17021013
- Lee KY, Russell SJ, Ussar S, Boucher J, Vernochet C, Mori MA, Smyth G, Rourk M, Cederquist C, Rosen ED, Kahn BB, Kahn CR. 2013. Lessons on conditional gene targeting in mouse adipose tissue. *Diabetes* **62**:864–874. DOI: <https://doi.org/10.2337/db12-1089>, PMID: 23321074
- Lee DV, Li D, Yan Q, Zhu Y, Goodwin B, Calle R, Brenner MB, Talukdar S. 2014. Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes. *PLoS One* **9**:e111767. DOI: <https://doi.org/10.1371/journal.pone.0111767>, PMID: 25365322
- Li Y, He Y, Qi L, Jaddoe VW, Feskens EJ, Yang X, Ma G, Hu FB. 2010. Exposure to the Chinese famine in early life and the risk of hyperglycemia and type 2 diabetes in adulthood. *Diabetes* **59**:2400–2406. DOI: <https://doi.org/10.2337/db10-0385>, PMID: 20622161
- Liao Y, Smyth GK, Shi W. 2014. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**:923–930. DOI: <https://doi.org/10.1093/bioinformatics/btt656>, PMID: 24227677
- Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**:402–408. DOI: <https://doi.org/10.1006/meth.2001.1262>, PMID: 11846609
- Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, Mohammadi M, Potthoff MJ. 2014. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. *Diabetes* **63**:4057–4063. DOI: <https://doi.org/10.2337/db14-0595>, PMID: 25008183
- McCarthy MI. 2010. Genomics, type 2 diabetes, and obesity. *New England Journal of Medicine* **363**:2339–2350. DOI: <https://doi.org/10.1056/NEJMr0906948>, PMID: 21142536

- Minard AY**, Tan SX, Yang P, Fazakerley DJ, Domanova W, Parker BL, Humphrey SJ, Jothi R, Stöckli J, James DE. 2016. mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. *Cell Reports* **17**:29–36. DOI: <https://doi.org/10.1016/j.celrep.2016.08.086>, PMID: 27681418
- Morrice N**, McIlroy GD, Tammireddy SR, Reekie J, Shearer KD, Doherty MK, Delibegović M, Whitfield PD, Mody N. 2017. Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice. *Scientific Reports* **7**:43782. DOI: <https://doi.org/10.1038/srep43782>, PMID: 28256636
- Morris AP**, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdóttir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko I, Kang HM, Dina C, Esko T, Fraser RM, Kanoni S, Kumar A, Lagou V, Langenberg C, Luan J, et al. 2012. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nature Genetics* **44**:981–990. DOI: <https://doi.org/10.1038/ng.2383>, PMID: 22885922
- Muise ES**, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP, Wong KK. 2008. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. *Molecular Pharmacology* **74**:403–412. DOI: <https://doi.org/10.1124/mol.108.044826>, PMID: 18467542
- Multhaup ML**, Seldin MM, Jaffe AE, Lei X, Kirchner H, Mondal P, Li Y, Rodriguez V, Drong A, Hussain M, Lindgren C, McCarthy M, Näslund E, Zierath JR, Wong GW, Feinberg AP. 2015. Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. *Cell Metabolism* **21**:138–149. DOI: <https://doi.org/10.1016/j.cmet.2014.12.014>, PMID: 25565211
- Ng SF**, Lin RC, Laybutt DR, Barres R, Owens JA, Morris MJ. 2010. Chronic high-fat diet in fathers programs β -cell dysfunction in female rat offspring. *Nature* **467**:963–966. DOI: <https://doi.org/10.1038/nature09491>, PMID: 20962845
- Nguyen S**, Meletis K, Fu D, Jhaveri S, Jaenisch R. 2007. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. *Developmental Dynamics* **236**:1663–1676. DOI: <https://doi.org/10.1002/dvdy.21176>, PMID: 17477386
- Nilsson E**, Jansson PA, Perfilyev A, Volkov P, Pedersen M, Svensson MK, Poulsen P, Ribel-Madsen R, Pedersen NL, Almgren P, Fadista J, Rönn T, Klarlund Pedersen B, Scheele C, Vaag A, Ling C. 2014. Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. *Diabetes* **63**:2962–2976. DOI: <https://doi.org/10.2337/db13-1459>, PMID: 24812430
- Nilsson E**, Matte A, Perfilyev A, de Mello VD, Kälälä P, Pihlajamäki J, Ling C. 2015. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. *The Journal of Clinical Endocrinology & Metabolism* **100**:E1491–E1501. DOI: <https://doi.org/10.1210/jc.2015-3204>, PMID: 26418287
- Nishikawa K**, Iwamoto Y, Kobayashi Y, Katsuoka F, Kawaguchi S, Tsujita T, Nakamura T, Kato S, Yamamoto M, Takayanagi H, Ishii M. 2015. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. *Nature Medicine* **21**:281–287. DOI: <https://doi.org/10.1038/nm.3774>, PMID: 25706873
- Ohno H**, Shinoda K, Ohyama K, Sharp LZ, Kajimura S. 2013. EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex. *Nature* **504**:163–167. DOI: <https://doi.org/10.1038/nature12652>, PMID: 24196706
- Olsson AH**, Volkov P, Bacos K, Dayeh T, Hall E, Nilsson EA, Ladvall C, Rönn T, Ling C. 2014. Genome-wide associations between genetic and epigenetic variation influence mRNA expression and insulin secretion in human pancreatic islets. *PLoS Genetics* **10**:e1004735. DOI: <https://doi.org/10.1371/journal.pgen.1004735>, PMID: 25375650
- Ozcan U**, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH, Hotamisligil GS. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science* **306**:457–461. DOI: <https://doi.org/10.1126/science.1103160>, PMID: 15486293
- Qureshi AT**, Chen C, Shah F, Thomas-Porch C, Gimble JM, Hayes DJ. 2014. Human adipose-derived stromal/stem cell isolation, culture, and osteogenic differentiation. *Methods in Enzymology* **538**:67–88. DOI: <https://doi.org/10.1016/B978-0-12-800280-3.00005-0>, PMID: 24529434
- Rajavelu A**, Tulyasheva Z, Jaiswal R, Jeltsch A, Kuhnert N. 2011. The inhibition of the mammalian DNA methyltransferase 3a (Dnmt3a) by dietary black tea and coffee polyphenols. *BMC Biochemistry* **12**:16. DOI: <https://doi.org/10.1186/1471-2091-12-16>, PMID: 21510884
- Robertson KD**. 2005. DNA methylation and human disease. *Nature Reviews Genetics* **6**:597–610. DOI: <https://doi.org/10.1038/nrg1655>, PMID: 16136652
- Robinson MD**, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**:139–140. DOI: <https://doi.org/10.1093/bioinformatics/btp616>, PMID: 19910308
- Rönn T**, Poulsen P, Hansson O, Holmkvist J, Almgren P, Nilsson P, Tuomi T, Isomaa B, Groop L, Vaag A, Ling C. 2008. Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle. *Diabetologia* **51**:1159–1168. DOI: <https://doi.org/10.1007/s00125-008-1018-8>, PMID: 18488190
- Sambeat A**, Gulyaeva O, Dempersmier J, Tharp KM, Stahl A, Paul SM, Sul HS. 2016. LSD1 Interacts with Zfp516 to Promote UCP1 Transcription and Brown Fat Program. *Cell Reports* **15**:2536–2549. DOI: <https://doi.org/10.1016/j.celrep.2016.05.019>, PMID: 27264172
- Samuel VT**, Shulman GI. 2012. Mechanisms for insulin resistance: common threads and missing links. *Cell* **148**:852–871. DOI: <https://doi.org/10.1016/j.cell.2012.02.017>, PMID: 22385956

- Sharma S, Taliyan R. 2016. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes. *Pharmacological Research* **113**:320–326. DOI: <https://doi.org/10.1016/j.phrs.2016.09.009>, PMID: 27620069
- Siersbæk M, Varticovski L, Yang S, Baek S, Nielsen R, Mandrup S, Hager GL, Chung JH, Grøntved L. 2017. High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss. *Scientific Reports* **7**:40220. DOI: <https://doi.org/10.1038/srep40220>, PMID: 28071704
- Soccio RE, Chen ER, Lazar MA. 2014. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. *Cell Metabolism* **20**:573–591. DOI: <https://doi.org/10.1016/j.cmet.2014.08.005>, PMID: 25242225
- Step SE, Lim HW, Marinis JM, Prokesch A, Steger DJ, You SH, Won KJ, Lazar MA. 2014. Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPAR γ -driven enhancers. *Genes & Development* **28**:1018–1028. DOI: <https://doi.org/10.1101/gad.237628.114>, PMID: 24788520
- Stresemann C, Lyko F. 2008. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. *International Journal of Cancer* **123**:8–13. DOI: <https://doi.org/10.1002/ijc.23607>, PMID: 18425818
- Sugii S, Olson P, Sears DD, Saberi M, Atkins AR, Barish GD, Hong SH, Castro GL, Yin YQ, Nelson MC, Hsiao G, Greaves DR, Downes M, Yu RT, Olefsky JM, Evans RM. 2009. PPAR γ activation in adipocytes is sufficient for systemic insulin sensitization. *PNAS* **106**:22504–22509. DOI: <https://doi.org/10.1073/pnas.0912487106>, PMID: 20018750
- Tan SX, Fisher-Wellman KH, Fazakerley DJ, Ng Y, Pant H, Li J, Meoli CC, Coster AC, Stöckli J, James DE. 2015. Selective insulin resistance in adipocytes. *Journal of Biological Chemistry* **290**:11337–11348. DOI: <https://doi.org/10.1074/jbc.M114.623686>, PMID: 25720492
- Tateishi K, Okada Y, Kallin EM, Zhang Y. 2009. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. *Nature* **458**:757–761. DOI: <https://doi.org/10.1038/nature07777>, PMID: 19194461
- Tobi EW, Goeman JJ, Monajemi R, Gu H, Putter H, Zhang Y, Slieker RC, Stok AP, Thijssen PE, Müller F, van Zwet EW, Bock C, Meissner A, Lumey LH, Eline Slagboom P, Heijmans BT. 2014. DNA methylation signatures link prenatal famine exposure to growth and metabolism. *Nature Communications* **5**:5592. DOI: <https://doi.org/10.1038/ncomms6592>, PMID: 25424739
- Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, Langenberg C, Hofmann OM, et al. 2010. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nature Genetics* **42**:579–589. DOI: <https://doi.org/10.1038/ng.609>, PMID: 20581827
- Volkmar M, Dedeurwaerder S, Cunha DA, Ndlovu MN, Defrance M, Deplus R, Calonne E, Volkmar U, Igoillo-Esteve M, Naamane N, Del Guerra S, Masini M, Bugliani M, Marchetti P, Cnop M, Eizirik DL, Fuks F. 2012. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. *The EMBO Journal* **31**:1405–1426. DOI: <https://doi.org/10.1038/emboj.2011.503>, PMID: 22293752
- Volkov P, Olsson AH, Gillberg L, Jørgensen SW, Brøns C, Eriksson KF, Groop L, Jansson PA, Nilsson E, Rönn T, Vaag A, Ling C. 2016. A genome-wide mQTL analysis in human adipose tissue identifies genetic variants associated with DNA methylation, gene expression and metabolic traits. *PLoS One* **11**:e0157776. DOI: <https://doi.org/10.1371/journal.pone.0157776>, PMID: 27322064
- Volkov P, Bacos K, Ofori JK, Esguerra JL, Eliasson L, Rönn T, Ling C. 2017. Whole-genome bisulfite sequencing of human pancreatic islets reveals novel differentially methylated regions in type 2 diabetes pathogenesis. *Diabetes* **66**:1074–1085. DOI: <https://doi.org/10.2337/db16-0996>, PMID: 28052964
- Wang H, Qiang L, Farmer SR. 2008. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. *Molecular and Cellular Biology* **28**:188–200. DOI: <https://doi.org/10.1128/MCB.00992-07>, PMID: 17954559
- Wei Y, Yang CR, Wei YP, Zhao ZA, Hou Y, Schatten H, Sun QY. 2014. Paternally induced transgenerational inheritance of susceptibility to diabetes in mammals. *PNAS* **111**:1873–1878. DOI: <https://doi.org/10.1073/pnas.1321195111>, PMID: 24449870
- Xie M, Hong C, Zhang B, Lowdon RF, Xing X, Li D, Zhou X, Lee HJ, Maire CL, Ligon KL, Gascard P, Sigaroudinia M, Tlsty TD, Kadlecsek T, Weiss A, O'Geen H, Farnham PJ, Madden PA, Mungall AJ, Tam A, et al. 2013. DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. *Nature Genetics* **45**:836–841. DOI: <https://doi.org/10.1038/ng.2649>, PMID: 23708189
- Ye J. 2013. Improving insulin sensitivity with HDAC inhibitor. *Diabetes* **62**:685–687. DOI: <https://doi.org/10.2337/db12-1354>, PMID: 23431009
- Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Boström KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, et al. 2008. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nature Genetics* **40**:638–645. DOI: <https://doi.org/10.1038/ng.120>, PMID: 18372903
- Zeng X, Jedrychowski MP, Chen Y, Serag S, Lavery GG, Gygi SP, Spiegelman BM. 2016. Lysine-specific demethylase 1 promotes brown adipose tissue thermogenesis via repressing glucocorticoid activation. *Genes & Development* **30**:1822–1836. DOI: <https://doi.org/10.1101/gad.285312.116>, PMID: 27566776
- Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A. 2008. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. *Diabetes* **57**:1246–1253. DOI: <https://doi.org/10.2337/db07-1476>, PMID: 18252893

Zhao J, Goldberg J, Bremner JD, Vaccarino V. 2012. Global DNA methylation is associated with insulin resistance: a monozygotic twin study. *Diabetes* **61**:542–546. DOI: <https://doi.org/10.2337/db11-1048>, PMID: 22210312